Although it shows blood pressure (BP) levels can be reduced to below the current guidelines set for cardiovascular risk reduction, research does not support additional reduction as a strategy to prevent progression of hypertensive nephrosclerosis.
Researchers with the African American Study of Kidney Disease and Hypertension (AASK) trial say their results do support the use of angiotensin-converting enzyme inhibitors as first-line therapy over beta-blockers and dihydropyridine calcium channel blockers in hypertensive nephrosclerosis patients.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!